

THE POWER OF PLUS

Where Partnership Intersects with Possibilities





Where Partnership Intersects with Possibilities



The Power of Plus

At Takeda, we're looking for partners who believe our global reach, deep scientific expertise and clinical excellence can help them bring their vision to market.

We've been putting patients first for more than 235 years. Our centuries-old values of integrity, fairness, honesty and perseverance guide how we operate and how we work with partners.

If better health and a brighter future for people everywhere is our why, partnering is our how. We believe deeply in the power of Takeda **plus** our partners.






Patient-centric, partner-focused

Our outside-in mindset is focused on identifying innovations both outside and within our walls. We think differently – and creatively – about how we work with our partners and build on our combined strengths across all stages of discovery, development and commercialization. The Power of Plus means creatively combining our expertise with yours to improve patient health.


Leveraging what we do best – together

At Takeda, we deeply value your company's expertise, skills and unique culture, and will help you leverage the benefits of teaming with Takeda: a flexible, people-oriented company; an ecosystem of academic institutions, nonprofit organizations, venture capital firms and biopharmaceutical peers; and a highly motivated alliance team with commercial expertise and a track record of success across the entire product lifecycle.

The background features a network diagram with several glowing blue nodes connected by thin white lines. The nodes are arranged in a roughly triangular pattern, with one node at the top left, one at the top right, and one in the center. The lines connect these nodes, creating a web-like structure. The overall aesthetic is futuristic and technological.

Unique approach – differentiated results

Takeda is open for business – open to exploring new and different ways of partnering with you. We've structured our partnering organization to support creative collaborations tailored to your unique needs, ranging from innovative deal structures to novel implementation models and beyond. Count on our alliance team to operate nimbly and follow through on our commitments.



Sharing success in the true spirit of partnership

How we operate and work with partners is guided by Takeda's core values, forged over 235-plus years. They are the inspiration for our spirit of collaboration and the foundation of how we pursue our mission "to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine."

MEET YOUR TEAM



Dan Curran, MD
Head, Center for
External Innovation
daniel.curran@takeda.com



Marcello Agosti
Head, Global Commercial
and Global Business
Development
marcello.agosti@takeda.com



Ken Araki
Corporate Development
ken.araki@takeda.com



Tauhid Ali, PhD
R&D “TAK-celerator”
Externalization Initiatives
tauhid.ali@takeda.com



John Bathery
US Business Development
john.bathery@takeda.com



Mike Broxson
R&D Business Development
mike.broxson@takeda.com



Dan Gandor
US Digital Accelerator
daniel.gandor@takeda.com

MEET YOUR TEAM



Misako Hamamura

Japan Business Development
misako.hamamura@takeda.com



Juan Harrison

Strategic Academic Alliances
juan.harrison@takeda.com



Andy Hull

Alliance Management
andy.hull@takeda.com



Jonathan Lanfear

Vaccines Business
Development
jonathan.lanfear@takeda.com



Graeme Martin, PhD

Takeda Ventures
graeme.martin@takeda.com



Andrew Morris

Emerging Markets Business
Development
andrew.morris@takeda.com



Sandra Nobre

Europe and Canada Business
Development
sandra.nobre@takeda.com



Nicole Mowad-Nassar

Technology External
Partnerships
nicole.mowad-nassar@takeda.com

The **pluses** of partnering with Takeda

- + Faster path through the product lifecycle
- + Creative, customized collaboration
- + Dedicated alliance management team and resources
- + Respect for your independence and decision-making
- + Clear two-way accountability

www.takeda.com

© Takeda Pharmaceutical Company Limited 2017. All Rights Reserved

ONCOLOGY

Crescendo Biologics + Takeda

Therapies for cancer indications with high unmet medical needs, including tumor targeting drug conjugates and immuno-oncology therapeutics



OUTSIDE-IN INNOVATION

Next generation of unique, small and customizable Humabody®-based therapeutics.



CRESCENDO BIOLOGICS

Proprietary Humabody®-based therapeutics

TAKEDA

Oncology expertise, including antibody drug conjugates

DEAL HIGHLIGHT

Developing the next generation of unique, small and customizable Humabody®-based therapeutics using highly modular and targeted therapies

RARE DISEASE



Ultragenyx + Takeda

Expedite early-stage drug discovery of innovative new therapies



ultragenyx
pharmaceutical

OUTSIDE-IN INNOVATION

Development of therapies for patients with rare diseases that have few or no treatment options.



Takeda



ULTRAGENYX

Strong patient-centric development and regulatory capabilities in rare disease space

TAKEDA

Early pipeline of therapies across a number of rare genetic diseases

DEAL HIGHLIGHT

Five-year collaboration enabling development of therapies for patients with rare diseases

CENTRAL NERVOUS SYSTEM



Cerevance + Takeda

7 of the 10 leading causes of disability worldwide are CNS disorders



cerevance

OUTSIDE-IN INNOVATION

Novel therapeutics
for neurological and
psychiatric disorders.



Takeda



CEREVANCE

The company will use new technology created in the Howard Hughes Medical Institute laboratory at Rockefeller University

TAKEDA

25-person neuroscience research team, fully equipped laboratory space, licenses to preclinical and clinical stage drug program portfolio

DEAL HIGHLIGHT

An entrepreneurial research setting to rapidly advance new technology and therapeutic treatments for brain diseases

CROSS-THERAPEUTIC AREAS



Bridge Medicines + Takeda

Accelerated path to innovative therapies to treat disease



BRIDGE
MEDICINES

OUTSIDE-IN INNOVATION

Advance promising early technologies in major academic institutions through human proof of concept.



Takeda



BRIDGE MEDICINES

Financial, operational and managerial support to move from proof-of-concept study to in-human clinical trial. Formed by Tri-Institutional Therapeutics Discovery Institute (TRI-TDI) and Takeda.


TAKEDA

Industry expertise across the lifecycle

DEAL HIGHLIGHT

Projects managed in a VC setting; transformational model strives to shave years off normal process

Seeking the best science, technologies and assets to collaborate on improving patient health



Oncology

- + Multiple myeloma
- + Other hematological malignancies
- + Solid tumors - GI, GU, lung and breast cancers
- + Novel targeted payload approaches - ADCs, PDCs, CD3 engagers, etc.
- + Novel immuno-oncology approaches
- + Novel approaches targeting protein homeostasis

Gastroenterology


- + Crohn's disease
- + Ulcerative colitis
- + GI Motility disorders
- + NASH
- + Celiac disease
- + Microbiome approaches



Seeking the best science, technologies and assets to collaborate on improving patient health

Central Nervous System

- + Treatment Resistant Depression (TRD)
- + Cognitive impairment associated with schizophrenia (CIAS) and/or negative symptoms
- + Neurodegenerative disorders and associated dementias



Research & Technologies

- + Immunoprofiling
- + Gut-targeted drug-delivery
- + 'Humanized' preclinical models for immuno-modulation